File this under ‘Now you see them, now you don’t.”
One might think that a pharmaceutical ingredients company that boasts clients in 80 countries, certification from several regulators and employs some 1,400 “fully trained” workers shouldn’t have anything to hide.
But that’s not what U.S. Food and Drug Administration inspectors found when they visited a Global Calcium plant in Bangalore, India, last summer, according to a Jan. 16 warning letter the agency sent the company. And the various manufacturing breaches that were uncovered by agency staffers underscores ongoing concerns over the quality of products made by India’s pharmaceutical industry.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in